KR20160068972A - 잔여 세포 배양 불순물의 제거 - Google Patents

잔여 세포 배양 불순물의 제거 Download PDF

Info

Publication number
KR20160068972A
KR20160068972A KR1020167013838A KR20167013838A KR20160068972A KR 20160068972 A KR20160068972 A KR 20160068972A KR 1020167013838 A KR1020167013838 A KR 1020167013838A KR 20167013838 A KR20167013838 A KR 20167013838A KR 20160068972 A KR20160068972 A KR 20160068972A
Authority
KR
South Korea
Prior art keywords
protein
interest
ion exchange
virus
dna
Prior art date
Application number
KR1020167013838A
Other languages
English (en)
Korean (ko)
Inventor
칸리 노만
에릭 수다
카일라 도우리스
루이즈 아스티가라가
패트릭 바스테크
바이샬리 야논
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160068972A publication Critical patent/KR20160068972A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167013838A 2013-11-15 2014-11-06 잔여 세포 배양 불순물의 제거 KR20160068972A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904747P 2013-11-15 2013-11-15
US61/904,747 2013-11-15
PCT/EP2014/073986 WO2015071177A1 (fr) 2013-11-15 2014-11-06 Élimination d'impuretés résiduelles de culture cellulaire

Publications (1)

Publication Number Publication Date
KR20160068972A true KR20160068972A (ko) 2016-06-15

Family

ID=56069432

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013838A KR20160068972A (ko) 2013-11-15 2014-11-06 잔여 세포 배양 불순물의 제거

Country Status (9)

Country Link
US (2) US20160287693A1 (fr)
EP (1) EP3068791B1 (fr)
JP (2) JP6373376B2 (fr)
KR (1) KR20160068972A (fr)
CN (1) CN105745218B (fr)
AU (1) AU2014350370B2 (fr)
CA (1) CA2930634C (fr)
ES (1) ES2817928T3 (fr)
WO (1) WO2015071177A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
CN105837667A (zh) * 2016-05-18 2016-08-10 北京天坛生物制品股份有限公司 去除重组汉逊酵母乙肝表面抗原中宿主细胞残留dna的方法
WO2019063849A1 (fr) * 2017-12-20 2019-04-04 Dsm Ip Assets B.V. Purification d'un polypeptide d'intérêt
CN108531462B (zh) * 2018-04-20 2021-03-30 华南农业大学 一种禽腺病毒精纯化的方法
EP3937911A4 (fr) * 2019-03-15 2023-01-11 3M Innovative Properties Company Fabrication d'un produit biopharmaceutique à l'aide de modèles causaux
EP3938930A4 (fr) 2019-03-15 2023-01-11 3M Innovative Properties Company Détermination de modèles causaux pour commander des environnements
CN117866038B (zh) * 2024-03-11 2024-05-28 北京百力格生物科技有限公司 纯化含有宿主核酸的带亲和标签的酸性蛋白的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (fr) 1974-01-14 1977-07-15 Sandoz Ag
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1997017450A2 (fr) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions et procedes de production de polypeptides heterologues sur pichia methanolica
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
HUP0202846A3 (en) 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
NZ525076A (en) * 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
UA87836C2 (ru) 2004-02-27 2009-08-25 Октафарма Аг Способ получения очищенных, безопасных с вирусологической точки зрения препаратов антител
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
KR20080111487A (ko) * 2006-03-20 2008-12-23 메다렉스, 인코포레이티드 단백질 정제 방법
EP2105736A1 (fr) 2008-03-28 2009-09-30 Novartis Ag Analyse ADN au moyen d'électrophorèse capillaire
EP2361304A2 (fr) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Nouveau procédé
EP2445925A1 (fr) * 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Purification de protéines par précipitation de l'acide caprylique (l'acide octanoïque)
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20110165676A1 (en) * 2009-11-06 2011-07-07 The Children's Mercy Hospital Method for decellularization
WO2011154976A2 (fr) 2010-06-08 2011-12-15 Panacea Biotec Limited Vaccin antigrippal amélioré
JP6373376B2 (ja) * 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去

Also Published As

Publication number Publication date
CN105745218A (zh) 2016-07-06
CN105745218B (zh) 2020-11-06
JP2017505283A (ja) 2017-02-16
US20160287693A1 (en) 2016-10-06
WO2015071177A1 (fr) 2015-05-21
AU2014350370A1 (en) 2016-06-02
CA2930634C (fr) 2023-05-09
AU2014350370B2 (en) 2017-04-13
ES2817928T3 (es) 2021-04-08
JP2018030885A (ja) 2018-03-01
JP6373376B2 (ja) 2018-08-15
US20190083603A1 (en) 2019-03-21
CA2930634A1 (fr) 2015-05-21
US10617753B2 (en) 2020-04-14
EP3068791B1 (fr) 2020-07-29
EP3068791A1 (fr) 2016-09-21

Similar Documents

Publication Publication Date Title
US10617753B2 (en) Removal of residual cell culture impurities
RU2197264C2 (ru) Способ получения поверхностных антигенных белков из вирусов гриппа, противогриппозная вакцина
Weigel et al. A flow-through chromatography process for influenza A and B virus purification
KR102542752B1 (ko) 바이러스에 대한 무균 정제 방법
EP2734619B1 (fr) Procédé de production d'antigène orthomyxoviral et de vaccins
EA014062B1 (ru) Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
JP2015521628A (ja) ウイルス様粒子の精製
KR20100075865A (ko) 바이러스성 백신의 제조 방법
JP7069281B2 (ja) インフルエンザ効力アッセイ
EP2351835B1 (fr) Procédé de production d'un antigène du virus de la grippe purifié
JP5823379B2 (ja) インフルエンザウイルスヘマグルチニンについてのアッセイ
Mandon et al. Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection
WO2011154976A2 (fr) Vaccin antigrippal amélioré
ES2975182T3 (es) Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
Fei et al. A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9)
US11339377B2 (en) SO3 chromatography for use in a method for virus purification
Weigel Development of chromatography-based purification processes for cell culture-derived influenza virus particles
KR20210133732A (ko) 인플루엔자 바이러스 항원 정제 조건 신속 확인 시험
AU2007221746A1 (en) Improvements in virus production

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application